Atlanta, GA, Sept. 14, 2026 (GLOBE NEWSWIRE) — Piedmont Realty Trust, Inc. (NYSE: PDM) (“Piedmont”) today announced that its operating partnership, Piedmont Operating Partnership, LP (the “Operating Partnership”), intends to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of exchangeable senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Piedmont will fully and unconditionally guarantee the notes on a senior, unsecured basis. The Operating Partnership also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $30,000,000 aggregate principal amount of notes.

The notes will be senior, unsecured obligations of the Operating Partnership, will accrue interest payable semi-annually in arrears and will mature on February 1, 2031, unless earlier repurchased, redeemed or exchanged. Noteholders will have the right to exchange their notes in certain circumstances and during specified periods. The Operating Partnership will settle exchanges by paying or delivering, as applicable, cash or a combination of cash and shares of Piedmont’s common stock, at the Operating Partnership’s election.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at the Operating Partnership’s option at any time, and from time to time, on or after August 6, 2029 and on or before the 60th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Piedmont’s common stock exceeds 130% of the exchange price for a specified period of time and certain other conditions are satisfied. In addition, the notes will be redeemable, in whole or in part (subject to certain limitations), at the Operating Partnership’s option at any time to the extent necessary to preserve Piedmont’s status as a real estate investment trust for U.S. federal income tax purposes, so long as certain conditions are satisfied. The Operating Partnership may also redeem the notes, in whole but not in part, at any time on or before the 60th scheduled trading day immediately before the maturity date, if certain conditions are satisfied and if the aggregate principal amount of notes that remains outstanding at such time is less than 10% of the aggregate principal amount of notes initially issued in connection with the offering. In each case, the redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If certain corporate events that constitute a “fundamental change” occur, then, subject to a limited exception, noteholders may require the Operating Partnership to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.

The notes will be entitled to the benefits of a registration rights agreement pursuant to which Piedmont will agree to register, under the Securities Act, the resale of the shares of Piedmont’s common stock, if any, issuable upon exchange of the notes within specified time periods and subject to certain limitations.

The interest rate, initial exchange rate and other terms of the notes will be determined at the pricing of the offering.

The Operating Partnership intends to use a portion of the net proceeds from this offering, together with the net proceeds from the settlement of certain forward sale transactions entered into under Piedmont’s at-the-market equity program, cash on hand and borrowings under its line of credit, to redeem all of its outstanding 9.250% senior notes due 2028 (the “2028 notes”) and pay the applicable make-whole premium and accrued and unpaid interest with respect thereto. If the initial purchasers exercise their option to purchase additional notes, the Operating Partnership will use the additional proceeds to redeem its outstanding 2028 notes and proportionally decrease the borrowings under its line of credit used to redeem the outstanding 2028 notes.

The Operating Partnership expects to use up to approximately $50 million of the net proceeds from the offering to repurchase shares of Piedmont’s common stock from certain purchasers of the notes in privately negotiated transactions effected through one of the initial purchasers or its affiliate concurrently with the pricing of the notes (the “concurrent share repurchase”). The price per share of Piedmont’s common stock repurchased in the concurrent share repurchase is expected to equal the last reported sale price per share of Piedmont’s common stock on the New York Stock Exchange as of the date of the pricing of the notes. This concurrent share repurchase could increase (or reduce the size of any decrease in) the market price of Piedmont’s common stock prior to, concurrently with or shortly after the pricing of the notes, and could result in a higher effective exchange price for the notes. The Operating Partnership cannot predict the magnitude of such market activity or the overall effect it will have on the market price of the notes and/or the market price of Piedmont’s common stock.

The offer and sale of the notes, the guarantee and any shares of Piedmont’s common stock issuable upon exchange of the notes have not been registered under the Securities Act or any other securities laws, and the notes, the guarantee and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. Although the Operating Partnership and Piedmont intend to enter into a registration rights agreement pursuant to which Piedmont will agree to register, under the Securities Act, the resale of the shares of Piedmont’s common stock, if any, issuable upon exchange of the notes, the registration rights agreement will contain significant limitations, and a resale registration statement may not be available at the time investors wish to resell the shares of Piedmont’s common stock, if any, issuable upon exchange of their notes. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of Piedmont’s common stock issuable upon exchange of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About Piedmont Realty Trust

Piedmont Realty Trust™ (NYSE: PDM) is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of approximately 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into premier “Piedmont PLACEs” that enhance each client’s workplace experience.

Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Piedmont intends for all such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act, as applicable. Such information is subject to certain known and unknown risks and uncertainties, which could cause actual results to differ materially from those anticipated. Therefore, such statements are not intended to be a guarantee of Piedmont’s performance in future periods. Such forward-looking statements can generally be identified by Piedmont’s use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue” or similar words or phrases that indicate predictions of future events or trends or that do not relate solely to historical matters, and include statements regarding whether the Operating Partnership will offer and issue the notes and the terms of the notes; the terms of the concurrent share repurchase; the intended use of the net proceeds from the offering; and the Operating Partnership’s expectations in respect of granting the initial purchasers an option to purchase additional notes. These statements are based on beliefs and assumptions of Piedmont’s management, which in turn are based on information available at the time the statements are made.

The following are some of the factors that could cause Piedmont’s actual results and its expectations to differ materially from those described in Piedmont’s forward-looking statements: economic, regulatory, socio-economic, technological (e.g., artificial intelligence and machine learning, virtual meeting platforms, etc.), and other changes that impact the real estate market generally, the office sector or the patterns of use of commercial office space in general, or the markets where we primarily operate or have high concentrations of revenue; the impact of competition on our efforts to renew existing leases or re-let space on terms similar to existing leases; lease terminations, lease defaults, lease contractions, or changes in the financial condition of our tenants, particularly by one of our large tenants; impairment charges on our long-lived assets or goodwill resulting therefrom; the success of our real estate strategies and investment objectives, including our ability to implement successful redevelopment and development strategies or identify and consummate suitable acquisitions and divestitures; the illiquidity of real estate investments, including economic changes, such as fluctuating interest rates, costs of construction, improvements and redevelopments, and available financing, which could impact the number of buyers/sellers of our target properties, and regulatory restrictions to which real estate investment trusts (“REITs”) are subject and the resulting impediment on our ability to quickly respond to adverse changes in the performance of our properties; the risks and uncertainties associated with our acquisition and disposition of properties, many of which risks and uncertainties may not be known at the time of acquisition or disposition; development and construction delays, including the potential of supply chain disruptions, and resultant increased costs and risks; future acts of terrorism, civil unrest, or armed hostilities in any of the major metropolitan areas in which we own properties; risks related to the occurrence of cybersecurity incidents, including cybersecurity incidents against us or any of our properties, vendors, or tenants, or a deficiency in our identification, assessment or management of cybersecurity threats impacting our operations and the public’s reaction to reported cybersecurity incidents, including the reputational impact on our business and value of our common stock; costs of complying with governmental laws, regulations and policies, including environmental standards imposed on office building owners; uninsured losses or losses in excess of our insurance coverage, and our inability to obtain adequate insurance coverage at a reasonable cost; additional risks and costs associated with directly managing properties occupied by government tenants, such as potential changes in the political environment, a reduction in federal or state funding of our governmental tenants, government layoffs or an increased risk of default by government tenants during periods in which state or federal governments are shut down or on furlough; significant price and volume fluctuations in the public markets, including on the exchange on which we listed our common stock; risks associated with incurring mortgage and other indebtedness, including changing capital reserve requirements on our lenders and rising interest rates for new debt financings; a downgrade in our credit ratings, the credit ratings of the Operating Partnership or the credit ratings of our or the Operating Partnership’s unsecured debt securities, which could, among other effects, trigger an increase in the stated rate of one or more of our unsecured debt instruments; the effect of future offerings of debt or equity securities on the value of our common stock; additional risks and costs associated with adverse U.S. global and economic conditions, inflation and potential increases in the rate of inflation, including the impact of a possible recession, uncertainty and volatility in financial markets, and any changes in governmental rules, regulations, and fiscal policies; uncertainties associated with environmental and regulatory matters; changes in the financial condition of our tenants directly or indirectly resulting from geopolitical developments that could negatively affect important supply chains and international trade, the termination or threatened termination of existing international trade agreements, or the implementation of tariffs or retaliatory tariffs on imported or exported goods; the effect of any litigation to which we are, or may become, subject; additional risks and costs associated with owning properties occupied by tenants in particular industries, such as oil and gas, hospitality, travel, co-working, etc., including risks of default during start-up and during economic downturns; changes in tax laws impacting REITs and real estate in general, as well as our ability to continue to qualify as a REIT under the Internal Revenue Code of 1986, as amended, or other tax law changes which may adversely affect our stockholders; the future effectiveness of our internal controls and procedures; and other factors, including the risk factors discussed under Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2025.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Piedmont cannot guarantee the accuracy of any such forward-looking statements contained in this press release, and Piedmont does not intend to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Research Analysts/ Institutional Investors Contact:
770-418-8592
investor.relations@piedmontreit.com

#FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Rotork Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
11/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

0.5p ordinary
  Interests

Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled:        
(2)   Cash-settled derivatives:

15,050,386 1.84 11,271 0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        

        TOTAL:

15,050,386 1.84 11,271 0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale

Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
0.5p ordinary Equity swap Reducing a long position 1,686 4.8420 GBP
0.5p ordinary Equity swap Reducing a long position 1,647 4.8433 GBP
0.5p ordinary Equity swap Reducing a long position 1,693 4.8427 GBP

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 14/09/2026
Contact name: Tom Howarth
Telephone number: +44 20 7144 7249

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Vilnius, Lithuania, Sept. 14, 2026 (GLOBE NEWSWIRE) —

Corrected Lithuanian language version of the announcement “Notice regarding the offering of EUR 19,000,000 2nd tranche of SUTNTIB AB Tewox bonds” published on 14 September 2026. In the original announcement, the English text was mistakenly inserted into the Lithuanian version. No changes have been made to the English text.

The full corrected announcement is provided below:

SUTNTIB AB Tewox, legal entity code 305733600, with its registered office at Jogailos g. 4, Vilnius, Republic of Lithuania (the Issuer).

The Issuer announces that, pursuant to the Issuer’s Base Prospectus approved by the Bank of Lithuania on 13 July 2026 (the Prospectus) and the approved Final Terms of the second tranche of the Issuer’s bonds (ISIN LT0000138281) (the Final Terms), the offering of the bonds under the Final Terms in the amount of up to EUR 19 million (subject to increase as provided for in the Final Terms) will be carried out in the Republic of Lithuania, the Republic of Latvia, and the Republic of Estonia from 14 September 2026 under the following main terms (other terms applicable to the offering are detailed in the Final Terms and the Prospectus):

  • Nominal Value of a Bond – EUR 1,000;
  • Issue Price of a Bond – EUR 1,008.99274 (with accrued interest);
  • Final Maturity Date – 21 February 2029;
  • Interest Rate – 8.00% (fixed) annually;
  • Yield – 8.00% annually;
  • Subscription channels – subscription by way of Nasdaq Auction through the Exchange Members (list https://nasdaqbaltic.com/statistics/lt/members);
  • Subscription Period – 14 September 2026 – 29 September 2026;
  • Exchange – the investors have an opportunity to exchange their bonds (ISIN LT0000409567) for the bonds of the new bond issue (ISIN LT0000138281) on a 1-to-1 basis through Nasdaq CSD;
  • Issue Date – 2 October 2026.

Before deciding to invest in the Bonds, each prospective investor shall read the Prospectus and Final Terms (as may be updated) with the attached relevant language summary. All aforementioned documents are attached herein and are published on the Issuer’s website at https://lordslb.lt/tewox_bonds/.

Contact person for further information:

Paulius Nevinskas
Manager of the Investment Company
paulius.nevinskas@lordslb.lt
https://lordslb.lt/tewox_bonds/

Attachments

Series  RIKV 26 1216 RIKV 27 0317
Settlement Date  09/16/2026 09/16/2026
Total Amount Allocated (MM)  16,202 26,500
All Bids Awarded At (Price / Simple interest)  97.974 / 8.181 96.020 / 8.199
Total Number of Bids Received  16 20
Total Amount of All Bids Received (MM)  18,702 33,400
Total Number of Successful Bids  13 17
Number of Bids Allocated in Full  13 17
Lowest Price / Highest Simple Interest Allocated  97.974 / 8.181 96.020 / 8.199
Highest Price / Lowest Simple Interest Allocated  98.006 / 8.049 96.095 / 8.038
Lowest Price / Highest Simple Interest Allocated in Full  97.974 / 8.181 96.020 / 8.199
Weighted Average of Successful Bids (Price/Simple Interest)  97.988 / 8.123 96.045 / 8.145
Best Bid (Price / Simple Interest)  98.006 / 8.049 96.095 / 8.038
Worst Bid (Price / Simple Interest)  97.960 / 8.238 96.001 / 8.240
Weighted Average of All Bids Received (Price / Simple Interest)  97.985 / 8.135 96.037 / 8.162
Percentage Partial Allocation (Approximate)  100.00 % 100.00 %
Bid to Cover Ratio  1.15 1.26

  • Independent DSMB reports no safety concerns to date and recommends continuing BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor
  • Seventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell’s novel immunotherapy approach
  • Phase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

Following its review, the DSMB raised no safety or other clinical concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell’s ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA), reflecting the significant unmet medical need in metastatic breast cancer.

“We are very encouraged by the DSMB’s seventh consecutive positive recommendation to continue BriaCell’s pivotal Phase 3 Bria-ABC study,” said Dr. William V. Williams, President and Chief Executive Officer of BriaCell. “This milestone represents continued progress in developing BriaCell’s novel immunotherapies for patients with urgent unmet medical needs.”

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the DSMB’s seventh consecutive positive recommendation, the favorable safety and tolerability profile of Bria-IMT™ plus an immune checkpoint inhibitor, the continued advancement of BriaCell’s pivotal Phase 3 Bria‑ABC study under FDA Fast Track designation, and Bria-IMT’s potential as a transformative immunotherapy for patients with metastatic breast cancer, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

Full-service, Texas-founded and headquartered financial services firm deepens commitment to the state’s growing capital markets

Parent company ticker symbol to change from TCBI to TXCP on November 9, 2026

DALLAS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced that it will transfer the primary listing of its common stock and its 5.75% non-cumulative perpetual preferred stock series B to the Texas Stock Exchange LLC (“TXSE”) from the Nasdaq Stock Market LLC (“Nasdaq”).

“After completing our successful transformation into the only full-service financial services firm founded and headquartered in Texas, bringing Texas Capital’s corporate listing home to the Texas Stock Exchange is the logical next step as we concurrently expand access to the global capital markets in Texas and beyond,” said Rob C. Holmes, Chairman, President & Chief Executive Officer of Texas Capital. “We are a proud early supporter of TXSE and view the launch of a world-class exchange in Texas as a landmark moment that further cements the state’s position as a premier destination for innovation and investment. TXSE has a proven leadership team, state-of-the-art trade matching technology, an enviable investor base and a shared listings approach, which will, in effect, have the issuer in a net positive cash position with the exchange.”

Texas Capital Bancshares, Inc. expects to commence trading as a TXSE-listed company upon market open on October 8, 2026, where its common and preferred stock will begin trading under the ticker symbol “TCBI” and “TCBI PRB”, respectively. Shortly thereafter on November 9, 2026, the company expects to change its ticker symbols to “TXCP” and “TXCP PRB”, respectively, marking another significant milestone in the firm’s history. The company’s common and preferred stock will continue trading on Nasdaq through market close on October 7, 2026. No action is required by stockholders in connection with the transfer.

“Texas Capital is the first home-grown, full-service financial services firm in the state of Texas, and we are proud to welcome their primary corporate listing home to the Texas Stock Exchange,” said TXSE Chairman and CEO James H. Lee. “Texas Capital has been a leader in developing capital markets in the Lone Star State, so it is fitting that they will be listed on the only national securities exchange built, headquartered, and incorporated in Texas.”

Today, Texas Capital combines deep Texas roots with a national reach, delivering a full suite of capabilities across Commercial Banking, Private Banking, Corporate Banking, Investment Banking and Treasury Solutions. The firm’s decision to list on TXSE reflects the successful completion of its transformation and represents the natural next step for a Texas-founded, Texas-headquartered institution built to serve clients across the country.

Bell Ringing
To commemorate Texas Capital Bancshares, Inc.’s move to TXSE, a closing bell ceremony is planned to be held in Dallas on November 9, 2026.

ABOUT TEXAS CAPITAL
Texas Capital Bancshares, Inc. (NASDAQ®: TCBI), a member of the Russell 2000® Index and the S&P MidCap 400®, is the parent company of Texas Capital Bank (“TCB”). Texas Capital is the collective brand name for TCB and its separate, non-bank affiliates and wholly owned subsidiaries. Texas Capital is a full-service financial services firm that delivers customized solutions to businesses, entrepreneurs and individual customers. Founded in 1998, the institution is headquartered in Dallas with offices in Austin, Fort Worth, Houston, San Antonio, Chicago, Los Angeles and New York City, and has a network of clients across the country. With the ability to service clients through their entire lifecycles, Texas Capital has established commercial banking, consumer banking, corporate and investment banking and wealth management capabilities. All services are subject to applicable laws, regulations and service terms. Deposit and lending products and services are offered by TCB. For deposit products, member FDIC. For more information, please visit texascapital.com.

Trading in securities and financial instruments, strategic advisory, and other investment banking activities are performed by TCBI Securities, Inc., doing business as Texas Capital Securities. TCBI Securities, Inc. is a member of FINRA and SIPC and has registered with the SEC and other state securities regulators as a broker dealer. TCBI Securities, Inc. is a subsidiary of TCB. All investing involves risks, including the loss of principal. Past performance does not guarantee future results. Securities and other investment products offered by TCBI Securities, Inc. are not FDIC insured, may lose value and are not bank guaranteed.

Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of and pursuant to the Private Securities Litigation Reform Act of 1995 regarding, among other things, TCBI transferring its listing to the TXSE, the expected benefits from and impact of the transfer of the listing, and trading under new ticker symbols. These statements are not historical in nature and may often be identified by the use of words such as “believes,” “projects,” “expects,” “may,” “estimates,” “should,” “plans,” “targets,” “intends” “could,” “would,” “anticipates,” “potential,” “confident,” “optimistic” or the negative thereof, or other variations thereon, or comparable terminology, or by discussions of strategy, objectives, estimates, trends, guidance, expectations and future plans.

Because forward-looking statements relate to future results and occurrences, they are subject to inherent and various uncertainties, risks, and changes in circumstances that are difficult to predict, may change over time, are based on management’s expectations and assumptions at the time the statements are made and are not guarantees of future results. Numerous risks and other factors, many of which are beyond management’s control, could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. While there can be no assurance that any list of risks is complete, important risks and other factors that could cause actual results to differ materially from those contemplated by forward-looking statements include, but are not limited to, operational, regulatory or technical challenges related to the TXSE-listing; and the risks and factors more fully described in TCBI’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents and filings with the SEC. The information contained in this communication speaks only as of its date. Except to the extent required by applicable law or regulation, we disclaim any obligation to update such factors or to publicly announce the results of any revisions to any of the forward-looking statements included herein to reflect future events or developments.

CONTACT: MEDIA CONTACT
Julia Monter
julia.monter@texascapital.com

INVESTOR CONTACT
Jocelyn Kukulka
investor.relations@texascapital.com

Cineplex also Delivers Highest Summer Box Office Period in Company History

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — (TSX: CGX) – Cineplex, Canada’s leading entertainment and media company, today reported August 2026 box office revenues of $98 million, the highest monthly box office performance in the Company’s history. August box office revenues doubled compared to the prior year, with Cineplex outperforming the domestic box office market during the month.

Period 2025 Box Office (i) 2026 Box Office (i) 2026 as a Percentage of 2025
July $72,722 $72,601 100%
August $49,087 $97,962 200%
Q3 to date $121,809 $170,563 140%
(i) Amounts are in thousands of dollars. 
 

Record August box office results capped off the strongest summer box office in Cineplex history, covering the period from the first Friday in May through Labour Day. Through August, third-quarter box office revenues were up 40 per cent compared to the prior year.

Driving both the record month of August and the strongest summer in Cineplex history were Spider-Man: Brand New Day and The Odyssey. Spider-Man: Brand New Day is currently the second highest-grossing release ever in Cineplex and continues to perform strongly. The Odyssey also delivered exceptional results and was a major driver of premium format attendance. Demand was particularly strong in IMAX 70MM, where Cineplex operates eight of the 41 theatres worldwide, one of the largest footprints of any exhibitor globally. Showtimes for The Odyssey continue to sell out across many of these locations.

Strong consumer demand to see these incredible films in premium formats also contributed to record guest spending. In August, approximately 54% of box office revenue came from premium experiences, and Cineplex achieved a Box Office Per Patron metric of more than $15.00. This marks the first time the Company has exceeded this milestone and highlights the continued popularity of its premium experiences.

Guest spending extended beyond the screen, with Cineplex generating the highest monthly Theatre Food Service revenue in its history. Furthermore, Cineplex’s Spider-Man: Brand New Day retail merchandise program became the largest film merchandise program in the Company’s history.

“The extraordinary response to Spider-Man: Brand New Day and The Odyssey helped deliver the highest August box office and most successful summer in Cineplex’s history,” said Ellis Jacob, President and Chief Executive Officer of Cineplex. “Canadians are choosing to experience great stories on the big screen and increasingly value experiencing those stories in a premium theatrical environment. The strength of this year’s slate, combined with a compelling lineup of highly anticipated films, including Clayface, The Hunger Games: Sunrise on the Reaping, Focker-in-Law, Hexed, Avengers: Doomsday, Dune: Part Three, and Jumanji: Open World, positions Cineplex for continued momentum as we build on a record summer.”

About Cineplex

Cineplex (TSX:CGX) is a top-tier Canadian brand that operates in the Film Entertainment and Content, Amusement and Leisure, and Media sectors. Cineplex offers a unique escape from the everyday to millions of guests through its circuit of 169 movie theatres and location-based entertainment venues. In addition to being Canada’s largest and most innovative film exhibitor, the company operates Canada’s favourite destination for ‘Eats & Entertainment’ (The Rec Room), complexes specially designed for teens and families (Playdium), and an entertainment concept that brings movies, amusement gaming, dining, and live performances together under one roof (Cineplex Junxion). It also operates successful businesses in cinema media (Cineplex Media), alternative programming (Cineplex Events) and motion picture distribution (Cineplex Pictures). Providing even more value for its guests, Cineplex is a partner in Scene+, Canada’s largest entertainment and lifestyle loyalty program.

Proudly recognized as having one of the country’s Most Admired Corporate Cultures, Cineplex employs over 10,000 people in its offices and venues across Canada. To learn more, visit Cineplex.com.

Investors:
Mahsa Rejali
Vice President, Corporate Development and Investor Relations
InvestorRelations@Cineplex.com

Media:
Michelle Saba, CPIR
Vice President, Communications
PressRoom@Cineplex.com

  • Mint features a new and innovative patch pump architecture 
  • Full Mint U.S. commercialization expected to begin in Q1 2027
  • Manufacturing capacity expected to produce at least 1.5 million disposable Mint units during 2027
  • 3D Intelligence, the Company’s next-generation insulin dosing algorithm, has been submitted to the FDA through a 510(k) application
  • Expectations to commercialize 3D Intelligence in the U.S. by the end of 2026 as iLet 3D™, and at the time of full Mint launch as Mint 3D™, subject to regulatory clearance by the FDA
  • Updated full year 2026 guidance

IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced U.S. Food and Drug Administration (FDA) clearance of Mint, the Company’s patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. Mint is expected to meaningfully expand the Company’s addressable insulin delivery market, particularly among people with diabetes seeking a patch pump form factor.

Additionally, the Company is unveiling 3D Intelligence, its anticipated next-generation insulin dosing algorithm, which has been submitted to the FDA through a 510(k) application. 3D Intelligence is designed with three algorithm experiences intended to enable a more customizable treatment approach tailored to each user’s unique insulin requirements.

Subject to regulatory clearance by the FDA, Mint 3D and iLet 3D will represent Beta Bionics’ next-generation automated insulin delivery (AID) platforms, designed to maximize user choice through optionality in hardware and algorithm experience.

“We believe that our next-generation AID platform, consisting of Mint 3D and iLet 3D, will represent a transformational advancement for people living with diabetes, subject to regulatory clearance by the FDA,” said Sean Saint, President & CEO of Beta Bionics. “Beta Bionics puts people with diabetes at the center of everything we do, and each element of Mint 3D and iLet 3D reflects that philosophy. Delivering choice is critical to the community we serve, and that is what Mint 3D and iLet 3D are intended to offer: the choice of wearing a patch pump or tubed pump along with an algorithm experience that is uniquely suited to each individual, all with a particular focus on improving affordability through our efforts to expand access for both iLet and Mint in the pharmacy channel.”

Expectations for Full Launch of Mint in the United States

The Company expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027, ahead of its previous target, and anticipates manufacturing capacity to produce at least 1.5 million total disposable units in the full year 2027. The Company believes it may be able to exceed the 1.5 million unit target by accelerating staffing, improving efficiency through additional automation, and enhancing manufacturing yield.

Mint is expected to launch exclusively through the pharmacy channel, with approximately 40% of insured U.S. lives expected to be able to purchase it using their pharmacy benefit. The Company anticipates coverage for Mint to increase to at least 50% of insured U.S. lives within the first year of full commercialization as it leverages its market access footprint.

Mint 3D Features Expected at the Time of Full Launch in the United States*

  • Transformative, two-piece reusable and disposable architecture
    • Smaller compared to the industry-leading patch pump
    • Seamless disposable patch change process with no phone re-pairing required
    • Firmware-over-the-air updates
    • Limits environmental waste
    • Three days of wear time, with an additional 12-hour grace period
    • 200-unit insulin reservoir
    • Never requires recharging
    • Waterproof with an IPX8 rating for up to 5 feet deep for 60 minutes
  • Comprehensive software and digital integration
    • Powered by Beta Bionics’ 3D Intelligence algorithm*
    • Compatible with industry-leading continuous glucose monitors: Dexcom G7, Dexcom G7 15 Day, and Abbott’s FreeStyle Libre 3 Plus
    • iOS and Android smartphone controlled

*Commercialization of Mint 3D is subject to regulatory clearance. The device is currently investigational and not available for sale. Actual product specifications and features may vary.

3D Intelligence Features & Expectations for Launch in the United States*

3D Intelligence represents the next generation of Beta Bionics’ fully adaptive automated insulin delivery technology. Building on the Company’s experience with iLet and its real-world use across more than 40,000 users, 3D Intelligence is designed to give people with diabetes greater choice in how their insulin delivery algorithm responds to their individual needs.

3D Intelligence is designed to offer clinicians three selectable algorithm experiences that they can choose based on each patient’s unique insulin needs.

  • Original – the algorithm currently available with iLet, with proven real-world experience across more than 40,000 users.**
  • Optimized – an enhanced experience that builds on the currently available algorithm and incorporates learnings from the Company’s real-world experience with iLet.
  • Conservative – an alternative experience designed to provide a more measured response when correcting high glucose levels.

Clinicians will be able to select the experience that best meets each user’s individual needs. Together, these three experiences are intended to provide greater personalization while preserving the core simplicity and automation of the currently available iLet experience.

Subject to regulatory clearance by the FDA, the 3D Intelligence insulin dosing algorithm is expected to power both iLet 3D and Mint 3D. Commercialization of iLet 3D in the United States is expected by the end of 2026, and commercialization of Mint 3D in the United States is expected simultaneous with the full Mint Iaunch in the first quarter of 2027, in each case, subject to regulatory clearance by the FDA.

*Commercialization of iLet 3D and Mint 3D is subject to regulatory clearance by the FDA. The devices are currently investigational and not available for sale. Actual product features may vary.

**Minor differences in adaptation compared to previous algorithm are not anticipated to have a significant impact on outcomes.

2026 Full Year Guidance & Key Considerations for 2027

For the full year 2026, the Company estimates total revenue of approximately $121 million to $126 million (previously $131 million to $136 million), reflecting a potential revenue deferral impact of up to $10 million in the fourth quarter of 2026 as new prospective iLet users could choose to await the launch of Mint.

  • During the full year 2027, the Company expects Mint to recapture any revenue lost in the fourth quarter of 2026.

For the full year 2026, the Company reiterates its expectations for 37% to 39% of new patient starts to be reimbursed through the pharmacy channel.

  • For the full year 2027, the Company expects pharmacy coverage for iLet to increase year over year, while the percentage of iLet new patient starts reimbursed through the pharmacy channel is expected to decline year over year as more pharmacy-covered individuals adopt Mint.
  • With the contribution from Mint, pharmacy channel revenue as a percentage of total revenue is expected to increase in 2027 relative to the prior year.

For the full year 2026, the Company reiterates its expectations for gross margin of 58.5% to 59.5%.

  • The Company expects Mint to be modestly dilutive to full year 2027 gross margin, and highly accretive to the Company’s long-term gross margin profile at scale.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Beta Bionics’ proprietary insulin dosing algorithm is the first FDA-cleared algorithm that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company”) regarding the potential clearance by the FDA, including of 3D Intelligence, and the timing thereof; the implications and potential benefits of the FDA’s clearance of Mint; the timing or certainty of full commercial launch of Mint, iLet 3D and Mint 3D in the United States and related updates; the Company’s anticipated manufacturing timeline and capacity of production of Mint at commercial launch and during 2027; the implications and potential benefits of 3D Intelligence, iLet 3D, and Mint 3D for people with diabetes; the anticipated specifications and features of 3D Intelligence and Mint 3D; the anticipated coverage for Mint at commercial launch and within the first year of commercialization; and the Company’s 2026 full year guidance and expectations for 2027 regarding estimates of revenue, including revenue deferral and revenue recapture, new patient starts reimbursed through the pharmacy channel, pharmacy channel coverage and gross margin. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, risks inherent in developing product candidates, the Company’s ability to obtain adequate financing to fund its product development and other expenses, the Company’s ability to manufacture and scale production of its products and manage its supply chain, the Company’s ability to obtain adequate reimbursement and payer coverage for its products, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry, future expenditures and the potential impacts of global macroeconomic conditions. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

Source: Beta Bionics, Inc.

ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) — Gray Media today launches new seasons of its popular weekday programs InvestigateTV+ and Aging Untold alongside the debut of a new weekday format for the uplifting newsmagazine program The Good Side.  

InvestigateTV+ returns for its fourth season, continuing its mission of delivering solutions-oriented, in-depth investigative journalism. Lee Zurik and Tisha Powell host the award-winning program, which airs weekdays across Gray’s markets as well as several non-Gray markets, clearing in over 72% of the U.S. daily. During the 2025-26 season, InvestigateTV+ reached nearly 13 million Adults 18+ (Source: Nielsen). The InvestigateTV team was recently honored with a prestigious National Edward R. Murrow Award for excellence in journalism. The program’s ongoing strong performance demonstrates that viewers remain hungry for impactful investigative stories that uncover critical issues and provide communities with real-world solutions.

Aging Untold enters its second season, providing practical solutions for aging adults and their families. The 30-minute, unscripted conversation-style show features returning experts “Sam” Cradduck, Amy Cameron O’Rourke, Katherine Ambrose, and Dr. Rhea Rogers, who offer guidance on navigating the aging process with dignity. Following its successful first season, which premiered in March 2026 and reached over seven million viewers 18+ (Source: Nielsen), the program continues to address the growing needs of older adults and caregivers. Viewers embraced the show’s debut season, finding comfort and valuable guidance in its honest, compassionate approach to a journey that touches every family. Heading into Season 2, Aging Untold has added new non-Gray markets and is now cleared in nearly 40% of the country.

The Good Side, which originated as a highly successful weekend program, officially transitions to a Monday-through-Friday schedule. Emmy and Edward R. Murrow award-winning journalist Debra Alfarone and new co-host Graham Ulkins lead the program, bringing viewers uplifting stories from communities across the country. By moving to a daily format, The Good Side will expand its focus on stories about people making a difference, community heroes, and positive regional stories that often go unnoticed.

“We are thrilled to return such a strong weekday lineup with these three exceptional programs that inform, inspire, and empower our audiences,” said Sandy Breland, Gray’s Chief Operating Officer. “Whether delivering investigations with impact, navigating the complexities of aging, or sharing uplifting stories, Gray Media remains dedicated to high-quality programming that resonates with viewers every single day.”

Viewers can check local listings or visit investigatetv.com, aginguntold.com, and thegoodside.tv for broadcast schedules and streaming options.

About Gray Media:

Gray Media, Inc. (NYSE: GTN) is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets. We serve 117 full-power television markets that collectively reach approximately 37% of US television households. The portfolio includes 78 markets with the top-rated television station and 101 markets with the first and/or second highest rated television station in average all-day ratings across the 116 of such markets that were measured by Nielsen in 2025. We also own the largest Telemundo Affiliate group with 46 markets and Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with the most advanced digital products and services. Our additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.

Gray Contact:

Sandy Breland, Executive Vice President, Chief Operating Officer, 404-266-8333

#        #        #

Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases

Deadline for Applications is October 2, 2026

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the ninth annual Cytokinetics Communications Grant Program. The program will award a number of grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) and heart failure communities. The grants are intended to support increased communications, awareness building and community engagement.

“Communications is often an underfunded area of patient advocacy, despite its potential to broaden reach and strengthen impact. When organizations have the resources to communicate effectively, they can connect patients and caregivers to critical information, amplify patient voices and build stronger partnerships that drive lasting impact across the communities they serve,” said Mary Pomerantz, Cytokinetics’ Senior Director of Patient Centricity and Corporate Responsibility. “Through our Communications Grant Program, we are honored to invest in meaningful, high-impact efforts that elevate patient perspectives, foster collaboration and expand access to support and resources.”

The Cytokinetics Communications Grant Program supports patient advocacy organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement. Funding from the Cytokinetics Communications Grant Program may help with programming or personnel, depending on each organization’s needs. The recipients of the 2026 Cytokinetics Communications Grants were Camp Taylor and The Canadian Sudden Arrhythmia Death Syndrome (SADS) Foundation.

Eligible organizations must have nonprofit organization or registered charity status in the United States, Canada, Europe or United Kingdom and serve the patient communities in HCM or heart failure. Organizations applying for the grant are required to submit a proposal outlining communication activities that the funding would support and the potential impact of the funding. Applications will be evaluated by a committee of representatives from Cytokinetics based on the proposal’s alignment with selection criteria. More details can be found at the application portal listed below. Recipients are responsible for providing an outcomes report to Cytokinetics to measure the impact and results of the funding at the end of 2027. Applications may now be submitted at https://www.cybergrants.com/Cytokinetics/communications_grant. The deadline to apply is October 2, 2026, and the grant recipients will be announced in January 2027.

For more information on the program, including eligibility guidelines, visit http://cytokinetics.com/responsibility/grants-and-giving/.

About the Cytokinetics Communications Grant Program

For the past nine years, the Cytokinetics Communications Grant Program has supported patient advocacy organizations to help expand their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement. Cytokinetics has no oversight, involvement or management of the actual projects, programs or outputs. The goal of the Communications Grant Program is to assist patient advocacy organizations by increasing resources in order to better support patient communities and bring increased disease awareness in the communities they serve.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union and the United Kingdom.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.